Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18769588 | 0.92 | SLC6A4 (0.54) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL18742717 | 0.91 | SLC6A4 (0.53) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL22947097 | 0.88 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL22946806 | 0.81 | SLC6A4 (0.44) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL18717567 | 0.79 | SCN10A (0.48) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| Hydrochloric Acid SCHEMBL31294712 | 0.77 | HDAC3 (0.43) | PIM1PIM2 | |
| SCHEMBL18151881 | 0.76 | SLC6A4 (0.49) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL10194679 | 0.76 | SLC6A4 (0.54) | SLC6A4SLC6A3SLC6A2KDM1ARCOR1 | |
| SCHEMBL254957 | 0.75 | MAPT (0.56) | PIM1PIM2MAPTEPHX2 | |
| SCHEMBL20267107 | 0.73 | SLC6A4 (0.51) | SLC6A4SLC6A3SLC6A2MAPTEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-2848618-B1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2017-05-11 | — | — | US | disclosed |
| CN-104245698-B | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL CO.,LTD. (JP) | 2016-11-30 | — | — | CN | disclosed |
| US-9469637-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-18 | — | — | US | disclosed |
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-16 | — | — | US | disclosed |
| EP-2848618-A1 | NITROGENATED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2015-03-18 | — | — | EP | disclosed |
| CN-104245698-A | Nitrogen-containing heterocyclic compound | TAKEDA PHARMACEUTICAL | 2014-12-24 | — | — | CN | disclosed |
| US-8518934-B2 | Oxycarbamoyl compounds and the use thereof | SHONOGI & CO., LTD. (JP) | 2013-08-27 | — | — | US | disclosed |
| EP-2346820-B1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO (JP) | 2013-02-13 | — | — | EP | disclosed |
| EP-2346820-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | Shionogi & Co., Ltd. (JP) | 2011-07-27 | — | — | EP | disclosed |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | PURDUE PHARMA L.P. | 2011-04-28 | — | — | US | disclosed |
| WO-2009151152-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | SHIONOGI & CO., LTD. (JP) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105373-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | SLC6A4 338/4885SLC6A3 68/4885SLC6A2 38/4885 |
| US-20110098276-A1 | OXYCARBAMOYL COMPOUNDS AND THE USE THEREOF | CACNA1B, ORAI1, CACNA1I | SLC6A4 838/4885SLC6A3 990/4885SLC6A2 780/4885 |
| US-20170129887-A1 | NITROGENATED HETEROCYCLIC COMPOUND | PDE2A, PDE5A, PDE3A | SLC6A4 338/4885SLC6A3 68/4885SLC6A2 38/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | SLC6A4 338/4885SLC6A3 68/4885SLC6A2 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.